Glenview Trust co Acquires New Position in Cardiff Oncology, Inc. (NASDAQ:CRDF)

Glenview Trust co acquired a new stake in Cardiff Oncology, Inc. (NASDAQ:CRDF) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 23,978 shares of the company’s stock, valued at approximately $104,000.

Other institutional investors also recently bought and sold shares of the company. GSA Capital Partners LLP grew its stake in shares of Cardiff Oncology by 432.7% during the 3rd quarter. GSA Capital Partners LLP now owns 186,650 shares of the company’s stock worth $498,000 after purchasing an additional 151,613 shares during the period. Bank of New York Mellon Corp grew its stake in Cardiff Oncology by 68.7% in the 4th quarter. Bank of New York Mellon Corp now owns 288,615 shares of the company’s stock valued at $1,253,000 after acquiring an additional 117,514 shares during the period. Barclays PLC boosted its stake in Cardiff Oncology by 291.9% during the 3rd quarter. Barclays PLC now owns 53,089 shares of the company’s stock worth $141,000 after purchasing an additional 39,542 shares during the last quarter. XTX Topco Ltd boosted its stake in Cardiff Oncology by 44.3% during the 3rd quarter. XTX Topco Ltd now owns 120,384 shares of the company’s stock worth $321,000 after purchasing an additional 36,947 shares during the last quarter. Finally, State Street Corp boosted its stake in Cardiff Oncology by 3.4% during the 3rd quarter. State Street Corp now owns 832,652 shares of the company’s stock worth $2,223,000 after purchasing an additional 27,628 shares during the last quarter. 16.29% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research analysts have recently commented on the company. Piper Sandler lifted their price target on Cardiff Oncology from $7.00 to $10.00 and gave the stock an “overweight” rating in a report on Friday, December 13th. HC Wainwright boosted their price objective on shares of Cardiff Oncology from $13.00 to $17.00 and gave the company a “buy” rating in a report on Friday, February 28th.

Cardiff Oncology Price Performance

NASDAQ CRDF opened at $3.79 on Wednesday. The company has a market cap of $252.13 million, a P/E ratio of -4.03 and a beta of 1.73. The stock has a 50-day moving average of $3.98 and a two-hundred day moving average of $3.38. Cardiff Oncology, Inc. has a 1-year low of $2.01 and a 1-year high of $6.42.

About Cardiff Oncology

Cardiff Oncology, Inc, a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab.